Please use this identifier to cite or link to this item:
|Title:||In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor||Authors:||Zhou, J.
|Keywords:||Acute myeloid leukemia
Tyrosine kinase inhibitor
Whole-body imaging technology
Wild-type FLT3 receptor
|Issue Date:||2008||Citation:||Zhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K. (2008). In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leukemia Research 32 (7) : 1091-1100. ScholarBank@NUS Repository. https://doi.org/10.1016/j.leukres.2007.11.025||Abstract:||Neoangiogenesis plays an important role in leukemogenesis. We investigated the in vivo anti-leukemic effect of ABT-869 against AML with wild-type FLT3 using RFP transfected HL60 cells with in vivo imaging technology on both the subcutaneous and systemic leukemia xenograft models. ABT-869 showed a five-fold inhibition of tumor growth in comparison with vehicle control. IHC analysis revealed that ABT-869 decreased p-VEGFR1, Ki-67 labeling index, VEGF and remarkably increased apoptotic cells in the xenograft models. ABT-869 also reduced the leukemia burden and prolonged survival. Our study supports the rationale for clinically testing an anti-angiogenesis agent in AML with wild-type FLT3. © 2007 Elsevier Ltd. All rights reserved.||Source Title:||Leukemia Research||URI:||http://scholarbank.nus.edu.sg/handle/10635/26977||ISSN:||01452126||DOI:||10.1016/j.leukres.2007.11.025|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 22, 2022
WEB OF SCIENCETM
checked on May 13, 2022
checked on May 12, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.